Cutaneous T-Cell Lymphoma: Current and Emerging Therapies

Area of Science:

• Oncology
• Dermatology
• Immunology

Background:

• Cutaneous T-cell lymphomas (CTCLs) are a group of heterogeneous T-cell malignancies primarily affecting the skin.
• Mycosis fungoides (MF) and Sézary syndrome (SS) are the most common subtypes, presenting diverse clinical and pathological features.
• While early MF is often managed with skin-directed therapies, advanced stages and SS require more aggressive treatment strategies.

Approach:

• This review synthesizes current multidisciplinary approaches for diagnosing and treating MF and SS.
• It emphasizes the integration of skin-directed therapies with emerging targeted and investigational systemic agents.
• Comprehensive management includes skin care, bacterial decolonization, and novel combination strategies.

Key Points:

• MF and SS represent the majority of CTCL cases, with varying prognoses.
• Successful clinical trials have led to FDA approvals for novel MF/SS therapies, improving response rates.
• Personalized medicine, including T helper 1 cytokine restoration and avoiding immunosuppression, is crucial for potential cures.

Conclusions:

• Effective management of MF/SS involves a multidisciplinary strategy combining local and systemic treatments.
• Advancements in targeted therapies and personalized medicine hold promise for improving survival and achieving cures.
• Restoring immune function and meticulous skin care are vital components of successful CTCL treatment.